Leerink Partners analyst Thomas Smith has maintained their bullish stance on KROS stock, giving a Buy rating yesterday.
Thomas Smith has given his Buy rating due to a combination of factors that highlight the potential of Keros Therapeutics’ pipeline, particularly the promising results from their Phase 1 trial of KER-065. The trial showed significant improvements in lean body mass and metabolic markers in healthy volunteers, which suggests potential efficacy in treating Duchenne Muscular Dystrophy (DMD). The company plans to engage with regulators and start a Phase 2 trial in early 2026, indicating a clear path forward for this promising treatment.
Furthermore, the safety profile of KER-065 was deemed acceptable, with manageable side effects, which supports its continued development. Beyond KER-065, Keros Therapeutics is also advancing other projects, such as the Phase 2 TROPOS trial for cibotercept in pulmonary arterial hypertension (PAH), which could further enhance the company’s value. These developments, coupled with the potential underappreciated value of Keros shares, underpin Thomas Smith’s optimistic outlook and Buy rating.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $40.00 price target.
KROS’s price has also changed dramatically for the past six months – from $58.070 to $10.190, which is a -82.45% drop .